Lexeo Therapeutics

We are excited to announce positive interim data for LX1001, the first-ever gene therapy to impact the underlying genetic cause of APOE4-associated Alzheimer’s disease. Treatment with LX1001 led to dose-dependent increases in protective APOE2 protein expression and improvements in Alzheimer's-associated tau biomarkers, measures which have been closely correlated with cognitive outcomes. LX1001 also demonstrated a favorable safety profile with no reports of ARIA. Data were presented earlier today by Dr. Kim Johnson in a late-breaking oral presentation at the CTAD Clinical Trials on Alzheimer's Disease conference and will be shared in a webcast at 7:00 AM ET. Additional information can be found in our press release: https://lnkd.in/eHeuVbxr

The #OneLexeo team had an amazing opportunity to partner with Life Science Cares New York last week and support 2024 Science Day! Over 50 high school students from schools across New York City visited the Lexeo office to learn more about careers in life sciences.   We are so passionate about our work at Lexeo, and we’re proud to inspire future generations about the impact they can have in biotech.

Congratulations to our scientific founder, Dr. Ron Crystal, the entire Weill Cornell Medicine team and our VP, Non-Clinical and Bioanalytical Development, Richie Khanna on the APOE2 Christchurch poster being accepted at the 2024 European Society of Gene and Cell Therapy Congress. The data highlights the impact of the Christchurch APOE2 variant on tau pathology in mice and provides further validation of the potential for gene therapy to treat Alzheimer’s disease.  Learn more about Lexeo’s pipeline including APOE2 Christchurch here: https://lnkd.in/d-Qvyyak

Lexeo is pleased to announce that new interim data from the ongoing Phase 1/2 trial of LX1001 for APOE4-associated Alzheimer’s disease have been selected as a late-breaking oral presentation at the upcoming annual CTAD Clinical Trials on Alzheimer's Disease Congress in Madrid, Spain.  Dr. Kim Johnson will be presenting on Wednesday, October 30th at 10:50AM CET (5:50AM EST). Find out more about the upcoming presentation here: https://lnkd.in/eFXe-j7d #APOE4 #AlzheimersAwarenes

We are pleased to share that our CEO, Nolan Townsend, has been recognized as one of Crain's New York Business 2024 Notable Black Leaders. This award honors Nolan’s significant accomplishments within the life sciences industry, his instrumental leadership at Lexeo, and his broader commitment to the New York community. Join us in congratulating Nolan on this well-deserved recognition! https://lnkd.in/ebu2C425 #OneLexeo

October marks Sudden Cardiac Arrest (SCA) Awareness Month. Family history is a significant risk factor for SCA. Did you know an estimated 60-75% of cases of sudden cardiac death may have genetic causes that remain unidentified?   Lexeo is developing a cardiac gene therapy candidate for individuals with arrhythmogenic cardiomyopathy caused by mutations in the PKP2 gene (PKP2-ACM), which can cause sudden cardiac arrest.   Learn more about our research: https://lnkd.in/eFbqFviF

Our CEO, Nolan Townsend, was recently featured in a Chardan panel on the future of cardiac genetic medicine. See below for more on the tailwinds fueling precision medicine in cardiac disease, including greater understanding of genetic drivers of disease, increasing genetic testing and regulatory flexibility.

Did you know that your genes can impact your risk of developing Alzheimer’s disease? Between 40 and 65% of those diagnosed with Alzheimer’s have the APOE4 gene.   Learn more about the impact of genetics in Alzheimer’s: https://lnkd.in/exNQ4FQh Learn more about our programs here: https://lnkd.in/g2BGvuSM #ENDALZ Alzheimer's Association®

Earlier this week, Team Lexeo was proud to support a packed few days of events with the Friedreich's ataxia community.   On Sunday, our team joined rideATAXIA in Philly to walk and bike—at the event and also from home!— followed by Friedreich's Ataxia Research Alliance (FARA) FA Symposium on Monday. We are grateful for the invitation to share recent clinical updates for our investigational therapy for FA cardiomyopathy and to participate in a Q&A panel.   Lexeo appreciates the opportunity to listen, learn, and connect with FA community members!   #FreidreichAtaxia #RareDisease #OneLexeo

We are thrilled to announce that Dr. Eric Adler, our Chief Medical Officer and Head of Research, has been named to the 2024 PharmaVoice 100 list in recognition of his outstanding contributions to the field of cardiovascular precision medicine. Dr. Adler also serves as a Professor of Medicine at the University of California, San Diego. He has been a long-time champion for people living with devastating cardiomyopathies, and he has pioneered research into novel treatment candidates at Lexeo and beyond. Congratulations Eric on this well-deserved achievement! Learn more about the 2024 PharmaVoice 100 here: https://lnkd.in/e9pFrenZ #OneLexeo